A modified form of vitamin B12 just did something that has stumped cancer researchers for decades — it slipped past the brain’s toughest security checkpoint and went straight for one of the deadliest tumors known to medicine.
Quick Take
- Researchers at the University at Buffalo engineered a B12-based compound called nitrosylcobalamin that crosses the blood-brain barrier and accumulates in glioblastoma tumor tissue.
- The compound uses the body’s own vitamin B12 delivery system to sneak a cancer-killing payload directly into brain tumor cells.
- Combined with standard chemotherapy, it showed strong synergistic effects in lab models — far more powerful than either treatment alone.
- This is early-stage, lab-only research with no human trials yet, and the road from promising lab results to approved therapy is long and brutal.
Why Glioblastoma Is So Hard to Kill
Glioblastoma is the most aggressive primary brain tumor in adults. The average survival after diagnosis is about 15 months. Surgery, radiation, and chemotherapy can slow it down, but they rarely stop it. The biggest problem is the blood-brain barrier — a tight wall of cells that blocks most drugs from reaching the brain. That wall protects healthy tissue, but it also shields tumors from treatment. Researchers have tried for years to crack it. Most fail.
How a B12 Molecule Became a Trojan Horse
Scientists know that cancer cells are hungry. They consume nutrients at a much faster rate than normal cells. Glioblastoma cells are especially greedy for vitamin B12, pulling it in through a receptor called CD320. Researchers at the University at Buffalo exploited that hunger. They attached nitric oxide — a molecule toxic to cancer cells — directly to a B12 compound, creating nitrosylcobalamin, or NO-Cbl. The tumor cells grab it through their own receptor, not knowing what’s inside.
In animal studies, NO-Cbl crossed the blood-brain barrier after a standard injection and concentrated inside tumor tissue. Tumor nitrate levels — a marker of nitric oxide delivery — peaked at 20.4 nanomoles per gram of tissue within 30 minutes and stayed elevated for 24 hours. [5] Meanwhile, levels in normal tissue dropped off quickly. That selectivity matters enormously. It suggests the compound is targeting the tumor, not flooding the whole brain with a toxic agent.
The Combination Effect That Changes the Math
NO-Cbl alone showed only modest cancer-killing power against glioblastoma cell lines in lab tests. Temozolomide, the standard chemotherapy drug used against glioblastoma, also showed modest results on its own. But when researchers combined NO-Cbl with temozolomide — and separately with a protein called TRAIL that triggers cancer cell death — something shifted. The combination produced a synergistic effect, meaning the result was far greater than adding the two treatments together. [2] Scientists confirmed this with a combination index below 1.0, which is the standard measure of true synergy.
Real Promise, Real Limits
The authors of the study published in Oncoscience in April 2026 are careful to call this a pilot study. No humans have taken NO-Cbl. There are no safety profiles, no toxicity data, and no dose-ranging studies in people. [3] The research was done entirely in cell cultures and animals. That is not a knock on the science — every approved drug started here. But it is a fact that only about 1 to 2 percent of brain cancer drug candidates that look promising in the lab ever make it to approval. [11] The gap between a petri dish and a patient is where most hopeful stories end.
The research also comes entirely from one institution. No major cancer centers have publicly announced involvement in NO-Cbl trials. That is not unusual at this stage, but it means the findings have not yet been stress-tested by independent teams with different equipment, different cell lines, and different incentives. Independent replication is how science earns trust. Until that happens, the results — while genuinely exciting — remain a strong hypothesis, not a proven therapy. The next step is a Phase I clinical trial to test safety in humans, and that process alone can take years.
Why This Still Matters Right Now
The mechanism behind NO-Cbl is what makes this more than just another lab curiosity. Using the body’s own vitamin transport system to smuggle a toxic payload past the blood-brain barrier is an elegant and logical strategy. It does not rely on brute force. It relies on biology. That approach has a better theoretical foundation than many compounds that have failed at this stage. If NO-Cbl clears safety hurdles in humans and the synergy seen in the lab holds up, it could genuinely change how glioblastoma is treated. That is a big if — but it is not an empty one.
Sources:
[2] Web – Vitamin B12-like drug shows promise in preclinical glioma study
[3] Web – Vitamin B12-Based Therapy Shows Tumor-Targeting … – Oncoscience
[5] Web – Response of Human Glioblastoma Cells to Vitamin B12 Deficiency
[11] Web – Glioblastoma preclinical models: Strengths and weaknesses
